Notice of Compliance with Conditions (NOC/c): Canada's Conditional Drug Approval Pathway

For a patient with an aggressive cancer or a rare, life-threatening condition, waiting for a full evidence package can mean waiting too long. Canada's answer to that tension is the Notice of Compliance with Conditions, or NOC/c. It lets Health Canada authorize a promising drug earlier, in exchange for a firm commitment from the sponsor to prove the clinical benefit after the drug reaches the market.

The pathway is powerful, but it is often misunderstood. An NOC/c is not a lighter form of approval that never has to be justified. It is a conditional market authorization backed by a signed, enforceable undertaking, and Health Canada can suspend it if the promised evidence does not arrive or does not hold up. This guide explains what an NOC/c is, when a drug qualifies, what conditions come attached, and how the pathway is changing as Canada moves to agile licensing in 2027.

Executive summary

The Notice of Compliance with Conditions is Health Canada's conditional drug approval pathway. It applies to drugs for serious, life-threatening, or severely debilitating conditions where there is promising evidence of clinical effectiveness and an unmet medical need. The sponsor gains earlier market access, and in return signs a Letter of Undertaking committing to confirmatory trials, enhanced monitoring, and specific labelling. The underlying Notice of Compliance is issued under section C.08.004 of the Food and Drug Regulations. Health Canada issues a Qualifying Notice setting the conditions, the sponsor responds with the Letter of Undertaking, and the NOC/c follows. Conditions stay in place until the confirmatory evidence satisfies Health Canada, at which point they are removed. If the confirmatory trials are not completed, or fail, Health Canada can suspend the authorization. From 1 April 2027, the new agile licensing terms and conditions framework will replace the NOC/c policy, so sponsors should understand both the current pathway and what is coming.

What is a Notice of Compliance with Conditions?

A Notice of Compliance with Conditions is a market authorization Health Canada grants to a promising drug for a serious, life-threatening, or severely debilitating condition, based on promising evidence of clinical effectiveness. In return, the sponsor agrees in writing to complete confirmatory studies and meet other conditions. The Notice of Compliance itself is issued under section C.08.004 of the Food and Drug Regulations, with a notation tied to a Letter of Undertaking.

The difference from a standard Notice of Compliance is the evidence threshold and the strings attached. A regular NOC reflects substantial evidence of safety and efficacy with no outstanding clinical questions. An NOC/c accepts promising evidence, which allows a sponsor to file earlier than would otherwise be possible, on the understanding that the remaining evidence will follow. The policy was built for a specific purpose: to give patients with serious diseases timely access to drugs that may offer significant benefit, while protecting the requirement that clinical benefit ultimately be proven.

When does a drug qualify for NOC/c?

A drug qualifies when it treats, prevents, or diagnoses a serious, life-threatening, or severely debilitating disease, shows promising evidence of clinical effectiveness, has an acceptable safety profile, is of high quality, and addresses an unmet medical need. Unmet need means either that no drug with a similar profile is marketed in Canada, or that the drug offers a significant improvement in the benefit and harm balance over what is available.

The evidence standard is the defining feature. Where a standard or priority review requires substantial evidence of effectiveness, the NOC/c policy accepts promising evidence: trials using a surrogate marker that still needs validation, a Phase II trial that would need Phase III confirmation, or a single small to moderate Phase III trial that would need to be confirmed. Examples of qualifying diseases named in the policy include HIV and AIDS, amyotrophic lateral sclerosis, and some cancers.

The conditions: what you agree to in the Letter of Undertaking

The conditions of an NOC/c are set out in a Letter of Undertaking that the sponsor submits before authorization. It must be signed by the chief executive officer or a designated signing authority, and it commits the company to confirmatory trials, enhanced post-market surveillance, and any agreed restrictions on advertising and distribution. In short, it is the contract that makes early access acceptable.

The confirmatory trials are the heart of the undertaking. The sponsor must design, carry out, and report trials that verify the clinical benefit, using established scientific standards, and initiate them in a timely way. Alongside that, the sponsor agrees to enhanced adverse reaction reporting and to a product monograph that discloses the NOC/c status so that prescribers understand the basis of the authorization.

Because the confirmatory trials carry the weight of the whole authorization, their design, conduct, and data integrity are under close scrutiny. Good clinical practice, robust trial registration, and reliable data are not optional add-ons here, they are what turns a conditional approval into a permanent one. Sponsors planning these trials should align early with Health Canada expectations, including clinical trial disclosure and transparency obligations.

The NOC/c process, step by step

The NOC/c process runs from submission to a Qualifying Notice, then to a Letter of Undertaking, and finally to the conditional authorization itself. Understanding the sequence helps sponsors plan timelines, because the time taken to agree the Letter of Undertaking directly affects the time to market.

1. File the submission. The sponsor files a New Drug Submission or a supplement supported by promising evidence of clinical effectiveness.
2. Receive the Qualifying Notice. If the drug qualifies, Health Canada issues a Qualifying Notice that sets out the confirmatory evidence, surveillance, and labelling conditions required.
3. Submit the Letter of Undertaking. The sponsor responds with a Letter of Undertaking, signed by the chief executive officer or designated authority, accepting the conditions.
4. Receive the NOC/c. Health Canada issues the Notice of Compliance with Conditions, and the drug may be marketed subject to the undertaking.
5. Meet the conditions. The sponsor runs the confirmatory trials, files annual progress reports, and maintains enhanced surveillance and the required labelling.
6. Submit the confirmatory results. When the trials are complete, the sponsor files a supplement containing the confirmatory results for Health Canada to review.
7. Remove the conditions. Once Health Canada is satisfied that all conditions are met, it removes them and the NOC/c becomes a regular Notice of Compliance.

Fulfilling and removing the conditions

Conditions are removed only when the sponsor has met every undertaking and submitted the supporting evidence, at which point Health Canada converts the NOC/c into a standard Notice of Compliance. Until then, the conditions remain fully in force, and the product monograph continues to disclose the NOC/c status.

The pathway has teeth. If a sponsor does not undertake or complete a confirmatory trial, or fails to provide results by the agreed date, Health Canada may treat that as reason to question whether the drug is safe or effective, and consideration can be given to invoking the suspension provisions of the Food and Drug Regulations. Health Canada can also suspend an NOC/c if the confirmatory trials fail to demonstrate clinical benefit or raise new safety concerns. That is why the integrity of the confirmatory data matters so much: weak trial conduct does not just delay the removal of conditions, it can put the authorization itself at risk. If a sponsor foresees that it cannot meet the agreed timelines, it can submit a new Letter of Undertaking proposing changes or an extension.

NOC/c compared with priority review and standard approval

How does NOC/c differ from a standard or priority review? Priority review speeds the assessment of a submission that already contains substantial evidence of effectiveness, shortening the review clock without changing the evidence bar. A standard review applies the full evidence standard at the normal pace. NOC/c is different in kind: it lowers the evidence threshold to promising evidence and attaches binding post-market conditions to make up the difference. The three are tools for different situations, and one product can move through more than one of them over its life.

In practice, a sponsor with a serious-disease product and a strong but still-maturing evidence base often pairs a priority review request with the NOC/c route, so the file is both assessed quickly and authorized conditionally. The key is to be clear about which lever you are pulling. Priority review buys speed on a complete package, while NOC/c buys early access on an incomplete one, at the cost of confirmatory obligations you must be resourced to deliver. Choosing the wrong tool, or assuming that one delivers what the other does, is a common and costly planning error. It is worth mapping your product against all three routes early, because the decision shapes your clinical plan, your budget, and the commitments your leadership will have to sign.

What changes in 2027: agile licensing and terms and conditions

The NOC/c policy is being replaced. Under the agile licensing amendments to the Food and Drug Regulations, Health Canada gains broad authority to impose terms and conditions on drug authorizations. The relevant provisions come into force on 1 April 2027, and the new terms and conditions framework is intended to take over the role the NOC/c policy plays today.

The agile licensing amendments were registered in late 2024 and give Health Canada two important new powers: to impose terms and conditions on any drug that has a Drug Identification Number, and to approve a new drug for a serious disease where there is an unmet need despite significant uncertainty about efficacy. Health Canada published draft guidance in December 2025, including a document intended to replace the NOC/c guidance. Sponsors should read the change alongside our explainer on Health Canada terms and conditions and agile licensing, and consider how it interacts with other flexible routes such as the foreign reliance pathway. The practical message is simple: the conditional approval concept is not going away, but the legal mechanism behind it is changing, and filings planned for 2027 and beyond should account for that.

NOC/c compliance checklist

Use this checklist when you are considering or managing an NOC/c.

• Confirm eligibility early. Test the disease severity, unmet need, and promising evidence against the policy before you build the submission strategy.
• Design the confirmatory trial up front. Have a credible, well designed confirmatory trial plan ready, not an afterthought once the NOC/c is granted.
• Prepare the Letter of Undertaking. Ensure it is signed by the appropriate authority and that the commitments are realistic and time-bound.
• Stand up enhanced pharmacovigilance. Put the enhanced adverse reaction reporting and annual progress reporting systems in place before launch.
• Control the product monograph and promotion. Reflect the NOC/c status in labelling and respect any advertising and distribution restrictions.
• Protect data integrity. Hold the confirmatory trials to good clinical practice, because weak data can put the authorization at risk.
• Track the 2027 transition. Monitor the agile licensing terms and conditions guidance and align filings planned for 2027 and beyond.

Common mistakes

• Treating an NOC/c as a full approval. The conditions are enforceable, and the authorization can be suspended if they are not met.
• Leaving the confirmatory trial until later. A vague or delayed confirmatory plan slows the whole process and invites regulatory concern.
• Confusing NOC/c with priority review. Priority review speeds a full evidence submission; NOC/c accepts promising evidence with conditions attached. They are different tools.
• Under-resourcing post-market obligations. Enhanced surveillance and annual reporting need dedicated systems, not a best effort after launch.
• Ignoring the coming framework change. Building a 2027 filing on the assumption that today's NOC/c policy will still be in place risks a late rework.

Frequently asked questions

What is the difference between an NOC and an NOC/c?

A Notice of Compliance is a standard market authorization granted when a drug shows substantial evidence of safety and efficacy with no outstanding clinical questions. A Notice of Compliance with Conditions is granted earlier, on promising evidence, for a serious condition with an unmet need, and it carries binding post-market conditions set out in a Letter of Undertaking. Both are issued under the Food and Drug Regulations.

What is a Letter of Undertaking?

It is the signed commitment a sponsor gives Health Canada before an NOC/c is issued. Signed by the chief executive officer or a designated authority, it sets out the confirmatory trials, enhanced surveillance, adverse reaction reporting, and any advertising or distribution restrictions the sponsor agrees to. It is the enforceable core of the conditional approval.

How does a sponsor remove the conditions?

The sponsor completes the confirmatory trials, submits the results in a supplement to the drug submission, and meets every other undertaking. Once Health Canada is satisfied that all conditions are fulfilled, it removes the conditions and the NOC/c becomes a regular Notice of Compliance.

Can Health Canada suspend an NOC/c?

Yes. If the confirmatory trials are not completed, results are not provided on time, the trials fail to show clinical benefit, or new safety concerns emerge, Health Canada can act, including invoking the suspension provisions of the Food and Drug Regulations. The conditional nature of the authorization is real, not symbolic.

Does NOC/c apply to generics and biologics?

The policy applies to New Drug Submissions and supplements, and it can also apply to Abbreviated New Drug Submissions in defined situations, for example where a reference product sponsor has not yet completed its confirmatory work. Biologic drugs reviewed by Health Canada can also fall within the pathway. The eligibility test is about the disease, the evidence, and the unmet need, not the product category alone.

When does agile licensing replace NOC/c?

The agile licensing terms and conditions provisions of the Food and Drug Regulations come into force on 1 April 2027 and are intended to replace the NOC/c policy. Health Canada published draft guidance on the new terms and conditions framework in December 2025. Until the framework takes effect, the NOC/c policy remains the operative pathway.

How MFLRC can help

MF License and Regulatory Consultants supports sponsors through conditional approval from strategy to post-market obligations. Our regulatory affairs and licensing services for pharmaceutical and biologic sponsors include NOC/c eligibility assessments, submission and Letter of Undertaking strategy, confirmatory trial planning, and pharmacovigilance system design.

We also help sponsors prepare for the shift to agile licensing, run quality and data integrity gap assessments on confirmatory programmes, and manage the lifecycle changes that follow approval, including post-approval change management under ICH Q12. Whether you are testing eligibility or converting an existing NOC/c into a full authorization, the aim is a defensible submission and a plan you can actually deliver.

Conclusion

The Notice of Compliance with Conditions is one of Canada's most valuable tools for getting promising drugs to patients who cannot wait, but it is a conditional bargain, not a shortcut. Earlier access comes with a signed commitment to prove clinical benefit, maintain enhanced surveillance, and control how the drug is presented. Sponsors who plan the confirmatory work and the post-market obligations from the start move through the pathway smoothly, while those who treat the conditions as an afterthought risk delay or suspension. With agile licensing arriving in 2027, the smart move is to master today's pathway and prepare for the framework that will replace it.

Sources and references

• Health Canada, Guidance Document: Notice of Compliance with Conditions (NOC/c)
• Health Canada, Notice of Compliance with conditions (NOC/c) overview
• Food and Drug Regulations (C.R.C., c. 870), section C.08.004, Justice Laws
• Canada Gazette, Part II, SOR/2024-238, Regulations Amending the Food and Drug Regulations (Agile Licensing)
• Health Canada, 2026 to 2028 Forward Regulatory Plan